PURPOSE: Treatment of synovial sarcoma (SS) is challenging because of its unpredictable clinical behavior. We reviewed our institutional experience with pediatric SS to identify prognostic indicators and survival outcomes. METHODS: We retrospectively reviewed all pediatric/adolescent patients (age<22 years) with confirmed SS treated from 1970 to 2010. Patient and clinical characteristics were evaluated for prognostic significance and survival outcomes. RESULTS: We identified 111 patients. The median age was 15.4 years. Sixty-seven tumors (60%) were monophasic, 42 (38%) were biphasic, and 2 (2%) were of unknown histology. Median follow-up was 5.3 years (range 0.8-36.8 years), 5-year overall survival (OS) was 73%, and 10-year OS was 65%. Greater tumor size (stratified as ≤5 cm, >5 cm, or ≥10 cm) (P=0.001) and depth (P=0.03) correlated with decreased OS. Primary tumor location in the upper extremity correlated with increased OS when compared with lower-extremity and central lesions (P=0.05). Bone and/or neurovascular invasion negatively impacted survival (P=0.02). Multivariate analysis revealed that tumor size (trichotomized) was the dominant and sole factor in discriminating survival risk. Neither radiotherapy nor chemotherapy correlated with improved 5-year survival. CONCLUSIONS: Tumor size, depth, invasion, and primary location affect survival in pediatric SS. The role of radiotherapy and chemotherapy for SS warrants future study.
PURPOSE: Treatment of synovial sarcoma (SS) is challenging because of its unpredictable clinical behavior. We reviewed our institutional experience with pediatric SS to identify prognostic indicators and survival outcomes. METHODS: We retrospectively reviewed all pediatric/adolescent patients (age<22 years) with confirmed SS treated from 1970 to 2010. Patient and clinical characteristics were evaluated for prognostic significance and survival outcomes. RESULTS: We identified 111 patients. The median age was 15.4 years. Sixty-seven tumors (60%) were monophasic, 42 (38%) were biphasic, and 2 (2%) were of unknown histology. Median follow-up was 5.3 years (range 0.8-36.8 years), 5-year overall survival (OS) was 73%, and 10-year OS was 65%. Greater tumor size (stratified as ≤5 cm, >5 cm, or ≥10 cm) (P=0.001) and depth (P=0.03) correlated with decreased OS. Primary tumor location in the upper extremity correlated with increased OS when compared with lower-extremity and central lesions (P=0.05). Bone and/or neurovascular invasion negatively impacted survival (P=0.02). Multivariate analysis revealed that tumor size (trichotomized) was the dominant and sole factor in discriminating survival risk. Neither radiotherapy nor chemotherapy correlated with improved 5-year survival. CONCLUSIONS:Tumor size, depth, invasion, and primary location affect survival in pediatric SS. The role of radiotherapy and chemotherapy for SS warrants future study.
Authors: Kyoung Jin Chang; Ilhan Lim; Joon Yeun Park; A Ra Jo; Chang Bae Kong; Won Seok Song; Wan Hyeong Jo; Soo Yong Lee; Jae Soo Koh; Byung Il Kim; Chang Woon Choi; Sang Moo Lim Journal: Nucl Med Mol Imaging Date: 2014-10-30
Authors: Daniel Orbach; Véronique Mosseri; Daniel Pissaloux; Gaelle Pierron; Bernadette Brennan; Andrea Ferrari; Frederic Chibon; Gianni Bisogno; Gian Luca De Salvo; Camille Chakiba; Nadège Corradini; Véronique Minard-Colin; Anna Kelsey; Dominique Ranchère-Vince Journal: Cancer Med Date: 2018-03-13 Impact factor: 4.452
Authors: C Moreau-Bachelard; L Campion; M Toulmonde; A Le Cesne; M Brahmi; A Italiano; O Mir; S Piperno-Neumann; V Laurence; N Firmin; N Penel; F Duffaud; C Chevreau; F Bertucci; B Narciso; P Dubray-Longeras; C Delcambre; E Saada-Bouzid; P Boudou-Rouquette; P Soulie; C Perrin; J Y Blay; E Bompas Journal: ESMO Open Date: 2022-02-21